Blood & Organ Banks in the US: Market Size, Businesses & Forecast 2026

The Blood & Organ Banks industry in the US encompasses establishments dedicated to the critical collection, testing, processing, storage, and distribution of human blood, blood components, and body organs for transplantation and transfusion. The industry operates as a vital node in the healthcare supply chain, directly bridging donor ecosystems with clinical providers like hospitals and surgical centers. According to the Health Resources and Services Administration (HRSA), there are 55 designated organ procurement organizations (OPOs) managing regional donor services across the country as of 2026. The sector's direction is increasingly shaped by advancements in perfusion technology and shift

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Blood & Organ Banks in the US industry cover?

This industry consists of specialized facilities and networks that manage the lifecycle of human biological resources intended for medical therapeutic use. Core operations involve the recruitment of donors, high-transparency screening, laboratory blood typing, virus testing, and temperature-controlled logistics. The scope extends across whole blood collection, specialized plasmapheresis, platelet extraction, and the recovery and preservation of vital organs such as kidneys, livers, and lungs.

• •Covers blood donor stations, human eye banks, sperm banks, and tissue repositories.
• •Includes specialized blood component manufacturing like red blood cells, plasma, and platelets.
• •Encompasses both mobile collection units and permanent processing facilities near hospital clusters.

Who operates in the industry and how is it structured?

The US market features a distinct blend of large non-profit humanitarian organizations, independent regional community centers, and specialized corporate operators. Blood banking leans heavily on large consolidated networks, whereas organ procurement is structurally divided into strictly monitored, government-designated regional monopolies. These entities work under federal mandates to secure biological materials and optimize clinical match metrics.

• •The American Red Cross stands as a primary market operator, providing approximately 40% of the nation's blood supply in fiscal year 2025.
• •The Organ Procurement and Transplantation Network (OPTN) serves as the unified national framework for matching organs.
• •Regional structures exist as a network of 55 distinct organ procurement organizations (OPOs) tracked by HRSA in 2026.

What drives demand in the industry?

Demand within this sector is fundamentally non-cyclical, dictated by surgical volumes, emergency trauma occurrences, and an aging demographic requiring chronic disease management. Structural shortages persist due to strict donor eligibility deferrals, matching criteria, and the brief biological shelf life of products. Innovation in complex surgeries, such as multi-organ transplants, continually elevates the volume requirements for both transfusion support and viable organs.

• •Chronic shortages are influenced by a maximum 42-day standard storage window for red blood cells.
• •Expanded patient blood management protocols in hospitals influence utilization efficiency and order patterns.
• •The increasing volume of complex surgical procedures and solid organ transplants drives consistent institutional demand.

Who are the notable companies in the industry?

While the domestic organ procurement side is non-profit and regionally isolated, the broader blood and commercial plasma collection landscape features prominent multinational operators and specialized medical tech entities. Intense operational coordination occurs around preservation logistics, testing protocols, and contract management for health systems. Major entities drive efficiency through advanced separation technology, automated donor screening, and cold-chain infrastructure.

• •CSL Plasma operates as a major commercial collector of human plasma for therapy development within the US market.
• •BioLife Plasma Services, a part of Takeda, manages an extensive network of specialized plasma collection centers across multiple states.
• •Octapharma Plasma is a prominent global operator heavily involved in the domestic collection and distribution of source plasma.
• •OneBlood operates as a major non-profit independent regional blood center network serving healthcare facilities across the Southeast US.

How is the industry regulated?

As biological drug products and clinical resources, blood and organ banking activities face stringent oversight from multiple federal bodies to protect public health. Establishments must strictly adhere to current Good Manufacturing Practices (cGMP), register active facilities, and report adverse donor or recipient events. Policy changes regularly target organ allocation methodologies to maximize equity and minimize geographic disparities.

• •The US Food and Drug Administration (FDA) regulates blood and plasma under biological drug protocols and enforces strict establishment registration.
• •The Department of Health and Human Services (HHS) and HRSA directly oversee OPO performance metrics, enforcement, and regional alignment.
• •Organ procurement is bound by the specific policies, data submission requirements, and bylaws of the OPTN.

Government, statistical and trade sources used for this Claight analysis.

• US Food and Drug Administration (FDA) ·
• Health Resources and Services Administration (HRSA) ·
• Organ Procurement and Transplantation Network (OPTN) ·
• American Red Cross Annual Report 2025